Gilead Sciences is investing an additional $11 billion into its U.S. operations, the company announced this week, bringing its total investments in U.S. manufacturing and R&D through 2030 to more than $32 billion.

“Our U.S. R&D and manufacturing investments in the U.S. will create $43 billion in value to the U.S. economy over the next five years through direct capital investment and job creation,” the company stated.

This investment further bolsters Gilead’s domestic research, development, and manufacturing capabilities while advancing the company’s mission to discover and develop life-changing medicines.

This next phase of investment will support the building three new facilities, upgrading three existing sites to expand U.S. manufacturing and R&D capabilities, and investing in new technology and advanced engineering initiatives. Moreover, the additional $11 billion will cover:

• $4 billion allocated to capital projects, including labs and equipment.
• $5 billion dedicated to technology, operations, and R&D site activities.
• $2 billion invested in digital and advanced engineering initiatives
• Creation of approximately 800 new direct jobs and support more than 2,200 indirect jobs by 2028.

These current investments further build on Gilead’s history of U.S. investment with $15 billion over the last 10 years and reinforces the company’s role as a key contributor to the U.S. biopharmaceutical industry and a vital partner in driving scientific innovation and solutions for our patients.

Several other pharmaceutical companies have recently announced plans to increase investments in the U.S. in anticipation of potential tariffs on the industry, including Roche, Novartis and Johnson & Johnson.